A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian ...

Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in ...

Dr Wong, you’ve implemented Lp(a) testing in your health care system. What lessons can you share for other health systems looking to do the same? In following the NLA recommendation to test Lp(a) ...

Panelists discuss how treatment success in immunoglobulin A (IgA) nephropathy extends beyond clinical trial end points to encompass sustained proteinuria reduction, stable kidney function, symptom ...

As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through ...

Drug companies and specialty distributors navigate challenges like profitability, supply chain volatility, regulatory complexities, and market pressures to build successful partnerships, said Natalie ...

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse ...

New research links arthritis to an increased risk of prostate cancer, highlighting the need for further studies on prevention ...

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health ...

Measles cases surge in the US as vaccination rates decline, raising concerns about outbreaks and public health under Robert F ...

Timely outpatient telepsychiatry care for Medicaid enrollees was associated with lower hospitalization rates and comparable ...